LBPMedicine(SH:688393) Sou Hu Cai Jing·2025-08-08 11:58Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Anbiping, which closed at 31.05 yuan, down 6.87%, with a rolling PE ratio of 1298.45 times, indicating a substantial overvaluation compared to the industry average [1] - Anbiping's total market capitalization is reported at 2.905 billion yuan, which is considerably lower than the industry average market capitalization of 11.731 billion yuan [2] - The company operates in the medical device sector, focusing on tumor screening and diagnostic reagents, automation equipment, and AI-assisted diagnostic software [1] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows that Anbiping achieved a revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.064 million yuan, reflecting a year-on-year decline of 238.49% [1] - The company's gross profit margin stands at 61.97%, indicating a relatively high profitability despite the revenue decline [1]